China's new crown vaccine listing (China's new crown vaccine listed company stock code)

China's new crown vaccine listing time:

December 31, 2020, the State Council Joint Prevention and Control Mechanism released, Sinopharm China Biological new crown inactivated vaccine has been approved by the State Drug Administration for conditional listing.

The available data show that the protection rate is 79.34%, achieving the unity of safety, efficacy, accessibility and affordability, and meeting the requirements of the World Health Organization and the relevant standards of the State Drug Administration. The durability and protective effect of vaccine immunization will continue to be observed. This is a hard-won achievement, and the launch of the Chinese vaccine has injected confidence into the global fight against the epidemic and provided strong support for the vaccine to become a global public **** product.

Currently the new crown vaccine, which ones? Which is the best?

Currently there are hundreds of units in the global research and development of new crown vaccines, mainly focusing on several technical routes, including inactivated vaccines, recombinant vaccines, vector vaccines, and nucleic acid vaccines.

These five technical routes, you can not simply say which technical route is better, to evaluate a vaccine, we must take into account its safety, efficacy, accessibility, affordability, which is the scientific evaluation of a vaccine.

The vaccine that is currently being used for emergency vaccination in China is the New Crown inactivated vaccine, and there is no alternative, and there is no evidence to prove which process is better.

Considering the existing need for immunization, any process of vaccine is acceptable for people with non-contraindications, as long as it is used for the purpose of preventing disease.